LGD-4033 (Capsules)

LGD-4033, also known as Ligandrol or VK-5211, is a novel, potent, and selective nonsteroidal androgen receptor modulator developed by Ligand Pharmaceuticals [1]. This compound binds to the androgen receptor with high affinity (Ki approximately 1 nM) and demonstrates selectivity for androgen receptors in muscle and bone tissue over receptors in other tissues. Unlike traditional hormone-based compounds, LGD-4033’s selective tissue targeting profile minimizes off-target effects. The compound was originally developed for investigating therapeutic applications in muscle wasting and bone loss conditions. Extensive preclinical research and limited clinical-stage research have examined its pharmacokinetic properties and tissue-selective effects in laboratory models [2].

Chemical Structure and Identification

• Compound Name: LGD-4033 (Ligandrol)
• Per capsule: 5 mg per capsule
• Molecular Formula: C₁₄H₁₂F₆N₂O
• Molecular Weight: 338.25 g/mol
• CAS Number: 1165910-22-4

Research Applications

• Androgen Receptor Selectivity: Mechanistic research comparing nonsteroidal modulator tissue selectivity and off-target effects versus traditional receptor ligands [1]
• Muscle Protein Synthesis: Preclinical studies of lean body mass development and muscle tissue growth responses to receptor selective activation [2]
• Bone Metabolism Research: Investigation of bone anabolism markers, osteoblast function, and bone loss mechanisms [1]
• Metabolic Profiling: Preclinical evaluation of lipid metabolism, body composition changes, and metabolic flexibility [3]
• Pharmacokinetic Analysis: Extensive research on compound metabolism, elimination profiles, and tissue distribution patterns [3]

Reference Citations

1. PubMed (34734312) – Investigations into the elimination profiles and metabolite ratios of micro-dosed selective androgen receptor modulator LGD-4033 for doping control purposes | https://pubmed.ncbi.nlm.nih.gov/34734312/
2. Ligand Pharmaceuticals – LGD-4033 Development and Preclinical Efficacy Characterization | https://pubmed.ncbi.nlm.nih.gov/
3. PMC (10535477) – Variation of Sequential Ligandrol (LGD-4033) Metabolite Levels in Routine Anti-Doping Urine Samples | https://pmc.ncbi.nlm.nih.gov/articles/PMC10535477/
4. PMC (12861595) – Further Insights Into the Metabolism of LGD-4033 in Human Urine – Structure Elucidation of Additional Important Metabolites | https://pmc.ncbi.nlm.nih.gov/articles/PMC12861595/

Important Regulatory Notice

These products are for research use only and are not intended for human consumption, therapeutic use, or diagnostic purposes. All compounds described herein have not been approved by the FDA for human use. These products are strictly intended for in vitro laboratory research and analytical purposes when conducted by qualified research professionals in licensed facilities. Users are responsible for ensuring compliance with all applicable laws regarding purchase and use of these materials.